400091 HIF-Hydroxylase Inhibitor, DMOG - CAS 89464-63-1 - Calbiochem

400091
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₆H₉NO₅ 89464-63-1

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      400091-50MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 50 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable 2-OG (2-oxoglutarate) analog that is expected to act as a competitive inhibitor against all 2-OG-dependent dioxygenases. Effectively upregulates normoxia HIF-α transcription activity (effective conc. = 1 mM in cultures) by inhibiting HIF-PH- (HIF-α-prolyl hydroxylase) catalyzed ODD (oxygen-dependent degradation domain) Prolyl hydroxylation (Pro564 and Pro530 in HIF-1α and HIF-2α, respectively) and aspartyl/asparanginyl β-hydroxylase-catalyzed CAD Asp hydroxylation (Asn803 and Asn851 in HIF-1α and HIF-2α, respectively), resulting in a blockage of pVHL (von Hippel-Lindau) ubiquitin ligase complex-mediated HIF-α degradation and a simultaneous promotion of HIF CAD (COOH-terminal activation domain) p300/CBP association. DMOG is also demonstrated to augment artery ligation-induced up-regulation of HIF-1α and FLK (by 100% and 40%, respectively, in 11 days; 8 mg/0.5 ml/animal/i.p.; q.o.d.) in muscle tissues in a murine ischaemic model in vivo.
          Catalogue Number400091
          Brand Family Calbiochem®
          SynonymsN-(Methoxyoxoacetyl)-glycine methyl ester, Dimethyloxalylglycine, HIF Prolyl Hydroxylase Inhibitor I, HIF Aspartyl β-Hydroxylase Inhibitor, HIF Asparanginyl β-Hydroxylase Inhibitor
          References
          ReferencesPollard, P.J., et al. 2008. Biochem. J. 416, 387.
          Chen, H., et al. 2006. Cancer Res. 66, 9009.
          Milkiewicz, M., et al. 2004. J. Physiol. 560, 21.
          Lando, D., et al. 2002. Science 295, 858.
          Jaakkola, P., et al. 2001. Science 292, 468.
          Product Information
          CAS number89464-63-1
          FormPink-white to peach-white
          Hill FormulaC₆H₉NO₅
          Chemical formulaC₆H₉NO₅
          Hygroscopic Hygroscopic
          Structure formula ImageStructure formula Image
          Applications
          ApplicationHIF-Hydroxylase Inhibitor, DMOG, CAS 89464-63-1, is a cell-permeable 2-oxoglutarate (2-OG) analog that acts as a competitive inhibitor against all 2-OG-dependent dioxygenases.
          Biological Information
          Purity≥98% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          400091

          References

          Reference overview
          Pollard, P.J., et al. 2008. Biochem. J. 416, 387.
          Chen, H., et al. 2006. Cancer Res. 66, 9009.
          Milkiewicz, M., et al. 2004. J. Physiol. 560, 21.
          Lando, D., et al. 2002. Science 295, 858.
          Jaakkola, P., et al. 2001. Science 292, 468.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision06-June-2015 JSW
          SynonymsN-(Methoxyoxoacetyl)-glycine methyl ester, Dimethyloxalylglycine, HIF Prolyl Hydroxylase Inhibitor I, HIF Aspartyl β-Hydroxylase Inhibitor, HIF Asparanginyl β-Hydroxylase Inhibitor
          DescriptionA cell-permeable 2-OG (2-oxoglutarate) analog that is expected to act as a competitive inhibitor against all 2-OG-dependent dioxygenases. Effectively upregulates normoxia HIF-α transcription activity (effective conc. = 1 mM in cultures) by inhibiting HIF-PH- (HIF-α-prolyl hydroxylase) catalyzed ODD (oxygen-dependent degradation domain) Prolyl hydroxylation (Pro564 and Pro530 in HIF-1α and HIF-2α, respectively) and aspartyl/asparanginyl β-hydroxylase-catalyzed CAD Asp hydroxylation (Asn803 and Asn851 in HIF-1α and HIF-2α, respectively), resulting in a blockage of pVHL (von Hippel-Lindau) ubiquitin ligase complex-mediated HIF-α degradation and a simultaneous promotion of HIF CAD (COOH-terminal activation domain) p300/CBP association. DMOG is also demonstrated to augment artery ligation-induced up-regulation of HIF-1α and FLK (by 100% and 40%, respectively, in 11 days; 8 mg/0.5 ml/animal/i.p.; q.o.d.) in muscle tissues in a murine ischaemic model in vivo.
          FormPink-white to peach-white
          CAS number89464-63-1
          Chemical formulaC₆H₉NO₅
          Structure formulaStructure formula
          Purity≥98% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage +2°C to +8°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesPollard, P.J., et al. 2008. Biochem. J. 416, 387.
          Chen, H., et al. 2006. Cancer Res. 66, 9009.
          Milkiewicz, M., et al. 2004. J. Physiol. 560, 21.
          Lando, D., et al. 2002. Science 295, 858.
          Jaakkola, P., et al. 2001. Science 292, 468.